156 related articles for article (PubMed ID: 37560219)
1. The suppression of ATR/Chk1 pathway by Elimusertib ATR inhibitor in triple negative breast cancer cells.
Haciefendi A; Guney Eskiler G
Am J Transl Res; 2023; 15(7):4902-4911. PubMed ID: 37560219
[TBL] [Abstract][Full Text] [Related]
2. The ATR inhibition by Elimusertib enhances the radiosensitivity of MDA-MB-231 triple negative breast cancer in vitro.
Guney Eskiler G; Halis H; Hamarat KF; Derlioglu RR; Ugurlu BT; Haciefendi A
Int J Radiat Biol; 2024; 100(5):715-723. PubMed ID: 38421209
[TBL] [Abstract][Full Text] [Related]
3. Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.
Manavella DD; McNamara B; Harold J; Bellone S; Hartwich TMP; Yang-Hartwich Y; Mutlu L; Zipponi M; Demirkiran C; Verzosa MS; Altwerger G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Dottino PR; Choi J; Alexandrov LB; Buza N; Hui P; Santin AD
Gynecol Oncol; 2023 Feb; 169():98-105. PubMed ID: 36525930
[TBL] [Abstract][Full Text] [Related]
4. Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets.
Sofianidi A; Dumbrava EE; Syrigos KN; Nasrazadani A
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539474
[TBL] [Abstract][Full Text] [Related]
5. Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibition.
Sundararajan V; Tan TZ; Lim D; Peng Y; Wengner AM; Ngoi NYL; Jeyasekharan AD; Tan DSP
J Pathol; 2023 Feb; 259(2):194-204. PubMed ID: 36373784
[TBL] [Abstract][Full Text] [Related]
6. The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
Sartori G; Tarantelli C; Spriano F; Gaudio E; Cascione L; Mascia M; Barreca M; Arribas AJ; Licenziato L; Golino G; Ferragamo A; Pileri S; Damia G; Zucca E; Stathis A; Politz O; Wengner AM; Bertoni F
Br J Haematol; 2024 Jan; 204(1):191-205. PubMed ID: 38011941
[TBL] [Abstract][Full Text] [Related]
7. Decarbamoyl mitomycin C (DMC) activates p53-independent ataxia telangiectasia and rad3 related protein (ATR) chromatin eviction.
Xiao G; Kue P; Bhosle R; Bargonetti J
Cell Cycle; 2015; 14(5):744-54. PubMed ID: 25565400
[TBL] [Abstract][Full Text] [Related]
8. ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress.
Myers K; Gagou ME; Zuazua-Villar P; Rodriguez R; Meuth M
PLoS Genet; 2009 Jan; 5(1):e1000324. PubMed ID: 19119425
[TBL] [Abstract][Full Text] [Related]
9. Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy.
Al-Subhi N; Ali R; Abdel-Fatah T; Moseley PM; Chan SYT; Green AR; Ellis IO; Rakha EA; Madhusudan S
Breast Cancer Res Treat; 2018 Jun; 169(2):277-286. PubMed ID: 29396668
[TBL] [Abstract][Full Text] [Related]
10. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage.
Ha K; Fiskus W; Rao R; Balusu R; Venkannagari S; Nalabothula NR; Bhalla KN
Mol Cancer Ther; 2011 Jul; 10(7):1194-206. PubMed ID: 21566061
[TBL] [Abstract][Full Text] [Related]
11. Withaferin A inhibits expression of ataxia telangiectasia and Rad3-related kinase and enhances sensitivity of human breast cancer cells to cisplatin.
Hahm ER; Lee J; Abella T; Singh SV
Mol Carcinog; 2019 Nov; 58(11):2139-2148. PubMed ID: 31441116
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
13. Prevention of DNA Replication Stress by CHK1 Leads to Chemoresistance Despite a DNA Repair Defect in Homologous Recombination in Breast Cancer.
Meyer F; Becker S; Classen S; Parplys AC; Mansour WY; Riepen B; Timm S; Ruebe C; Jasin M; Wikman H; Petersen C; Rothkamm K; Borgmann K
Cells; 2020 Jan; 9(1):. PubMed ID: 31963582
[TBL] [Abstract][Full Text] [Related]
14. Multi-Level Control of the ATM/ATR-CHK1 Axis by the Transcription Factor E4F1 in Triple-Negative Breast Cancer.
Batnini K; Houles T; Kirsh O; Du Manoir S; Zaroual M; Delpech H; Fallet C; Lacroix M; Le Cam L; Theillet C; Sardet C; Rodier G
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012478
[No Abstract] [Full Text] [Related]
15. Selective Inhibition of ATM-dependent Double-strand Break Repair and Checkpoint Control Synergistically Enhances the Efficacy of ATR Inhibitors.
Turchick A; Zimmermann A; Chiu LY; Dahmen H; Elenbaas B; Zenke FT; Blaukat A; Vassilev LT
Mol Cancer Ther; 2023 Jul; 22(7):859-872. PubMed ID: 37079339
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells.
Kim HJ; Min A; Im SA; Jang H; Lee KH; Lau A; Lee M; Kim S; Yang Y; Kim J; Kim TY; Oh DY; Brown J; O'Connor MJ; Bang YJ
Int J Cancer; 2017 Jan; 140(1):109-119. PubMed ID: 27501113
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.
Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
Mol Cancer Res; 2020 Jan; 18(1):91-104. PubMed ID: 31649026
[TBL] [Abstract][Full Text] [Related]
18. Ultrasound activates ataxia telangiectasia mutated- and rad3-related (ATR)-checkpoint kinase 1 (Chk1) pathway in human leukemia Jurkat cells.
Furusawa Y; Iizumi T; Fujiwara Y; Hassan MA; Tabuchi Y; Nomura T; Kondo T
Ultrason Sonochem; 2012 Nov; 19(6):1246-51. PubMed ID: 22571845
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the ATR-DNAPKcs-RB axis drives G1/S-phase transition and sensitizes triple-negative breast cancer (TNBC) to DNA holliday junctions.
Hu YM; Liu XC; Hu L; Dong ZW; Yao HY; Wang YJ; Zhao WJ; Xiang YK; Liu Y; Wang HB; Yin QK
Biochem Pharmacol; 2024 May; 225():116310. PubMed ID: 38788960
[TBL] [Abstract][Full Text] [Related]
20. 4-Hydroxynonenal induces G2/M phase cell cycle arrest by activation of the ataxia telangiectasia mutated and Rad3-related protein (ATR)/checkpoint kinase 1 (Chk1) signaling pathway.
Chaudhary P; Sharma R; Sahu M; Vishwanatha JK; Awasthi S; Awasthi YC
J Biol Chem; 2013 Jul; 288(28):20532-46. PubMed ID: 23733185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
